missing translation for 'onlineSavingsMsg'
Läs mer
Läs mer
Invitrogen™ GPR37 Monoclonal Antibody (436923)
Beskrivning
Reconstitute at 0.5 mg/mL in sterile PBS.
Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson disease identified to date. The function of Park2 is not well-known; however, it may play a role in the ubiquitin-mediated proteolytic pathway. Mutations in this gene are known to cause autosomal recessive juvenile parkinsonism. Alternative splicing of this gene produces three known products of undetermined function. Panneuronal expression of Parkin substrate Pael-R causes age-dependent selective degeneration of Drosophila dopaminergic (DA) neurons; coexpression of Parkin degrades Pael-R and suppresses its toxicity.
Specifikationer
Specifikationer
| Antigen | GPR37 |
| Användningsområden | Flow Cytometry |
| Klassificering | Monoclonal |
| Klona | 436923 |
| Koncentration | 0.5 mg/mL |
| Konjugera | Unconjugated |
| Formulering | PBS with 5% trehalose and no preservative |
| Gen | GPR37 |
| Genaccessionsnr. | O15354 |
| Gene Alias | AI848630; EDNRBL; endothelin B receptor-like protein 1; ETBR-LP-1; G protein-coupled receptor 37; G protein-coupled receptor 37 (endothelin receptor type B-like); Gpcr/cns1; Gpr37; G-protein coupled receptor 37; G-protein coupled receptor CNS1; hET(B)R-LP; Het-b-r-lp; Pael receptor; PAELR; Pael-R; parkin-associated endothelin B-like receptor; Parkin-associated endothelin receptor-like receptor; probable G-protein coupled receptor 37; prosaposin receptor GPR37 |
| Visa mer |
Produkttitel
Genom att klicka på Skicka bekräftar du att du kan bli kontaktad av Fisher Scientific angående feedbacken du har lämnat i detta formulär. Vi kommer inte att dela din information för andra ändamål. All kontaktinformation som tillhandahålls ska också underhållas i enlighet med vår Sekretesspolicy.
Hittar du en möjlighet till förbättring?